Hologic Q1 2025 Earnings Report
Key Takeaways
Hologic reported first quarter 2025 financial results with revenue of $1,021.8 million, a 0.9% increase year-over-year. GAAP diluted EPS was $0.87, while non-GAAP diluted EPS reached $1.03, hitting the high end of the guidance. The company lowered its full-year GAAP EPS guidance but maintained its non-GAAP EPS guidance.
Revenue increased by 0.9% to $1,021.8 million, with constant currency growth of 1.0%, aligning with guidance.
Diagnostics revenue grew by 5.1% to $470.6 million, driven by molecular diagnostics sales.
Breast Health revenue decreased by 2.3% to $369.1 million, primarily due to lower mammography capital equipment sales.
The company repurchased 6.8 million shares for $517 million during the quarter.
Hologic
Hologic
Hologic Revenue by Segment
Hologic Revenue by Geographic Location
Forward Guidance
Hologic provided financial guidance for the second quarter and full year 2025, lowering the full-year revenue guidance based on currency headwinds and weakness in breast health capital sales, while maintaining the full-year guidance for non-GAAP EPS.
Positive Outlook
- Full year non-GAAP EPS guidance maintained.
- Full year non-GAAP tax rate of approximately 19.5% expected.
- Diluted shares outstanding of approximately 230 million expected for the full year.
- Second quarter revenue expected to be $995 - $1,005 million.
- Second quarter GAAP EPS expected to be $0.80 - $0.83.
Challenges Ahead
- Full year revenue guidance lowered to $4,050 - $4,100 million.
- Lowered revenue guidance is based on currency headwinds.
- Lowered revenue guidance is based on weakness in breast health capital sales.
- Second quarter revenue expected to decline by (2.2%) to (1.3%) reported.
- Second quarter non-GAAP EPS expected to be $1.00 - $1.03.